🟡 Preliminary Evidence
A new analysis of inosine pranobex, an existing antiviral medication, suggests potential therapeutic value against SARS-CoV-2, according to a research letter by Dr. Simon Reich published in the International Journal of Infectious Diseases in August 2026. Dr. Reich’s correspondence examines the drug’s mechanisms and clinical potential as researchers continue searching for effective COVID-19 treatments.
Key takeaways
- Inosine pranobex demonstrates antiviral properties that may be effective against SARS-CoV-2, according to Dr. Simon Reich’s analysis
- The drug is already approved for other viral infections, potentially accelerating clinical evaluation
- Further clinical trials are needed to establish safety and efficacy for COVID-19 treatment
Study at a Glance
| Source | International Journal of Infectious Diseases |
| Study type | Research correspondence |
| Focus | Antiviral mechanisms analysis |
| Drug status | Currently approved for other indications |
| Publication date | August 2026 |
COVID-19 Treatment Development Timeline
Major antiviral approvals since pandemic start
Source: International Journal of Infectious Diseases, 2026 | Georgian Medical Journal News
Established Drug with New Potential
Inosine pranobex has been used clinically for decades to treat various viral infections, including herpes simplex and human papillomavirus.
Dr. Simon Reich’s analysis, published in the International Journal of Infectious Diseases, examines how these established mechanisms might translate to SARS-CoV-2 treatment. The research builds on previous work by Petersen and Hviid, who initially proposed investigating inosine pranobex for COVID-19 applications.
Mechanism of Action Against Coronaviruses
According to Reich’s analysis, the drug’s potential effectiveness against SARS-CoV-2 stems from its ability to interfere with viral replication while simultaneously boosting host immune responses. Reich’s analysis suggests that inosine pranobex enhances interferon production and T-cell activity, both crucial components of the body’s antiviral defense system.
Clinical experience with inosine pranobex in other viral infections provides a foundation for understanding its safety profile and dosing considerations, though specific COVID-19 applications would require dedicated clinical evaluation.
For more information on clinical updates and emerging treatments, readers can follow ongoing research developments through peer-reviewed publications.
Clinical Development Pathway
The existing approval status of inosine pranobex for other indications could potentially streamline the regulatory pathway for COVID-19 applications. However, Reich’s correspondence emphasizes that rigorous clinical trials remain essential to establish both safety and efficacy in this new context.
The research adds to a growing body of new studies exploring repurposed medications for COVID-19 treatment, reflecting the ongoing scientific effort to expand therapeutic options.
Inosine pranobex shows promise as a potential COVID-19 treatment through its dual action of viral inhibition and immune enhancement, building on decades of clinical experience with other viral infections.
— Dr. Simon Reich, International Journal of Infectious Diseases (2026)
What this means
Frequently asked questions
Is inosine pranobex currently available for COVID-19 treatment?
No, inosine pranobex is not currently approved for COVID-19 treatment. While the drug is approved for other viral infections, specific COVID-19 applications would require clinical trials and regulatory approval.
How does inosine pranobex work against viruses?
According to Reich’s analysis, the drug works through multiple mechanisms including enhanced interferon production, improved T-cell function, and direct antiviral effects. These actions help the immune system fight viral infections more effectively.
What are the next steps for this research?
Clinical trials would be needed to test safety and efficacy specifically for COVID-19 treatment. The existing safety profile from other indications may help inform study design and regulatory pathways.
As the scientific community continues to investigate new therapeutic approaches for COVID-19, research like Reich’s correspondence provides valuable insights into potential treatment options. The established safety profile of inosine pranobex, combined with its antiviral mechanisms, makes it a compelling candidate for further clinical investigation in the ongoing effort to improve patient outcomes.
Source: Re: Petersen E, Hviid AP. Inosine pranobex as a treatment of SARS-CoV-2? Int J Infect Dis. 2026
Was this article helpful?
100% of readers found this helpful (2 votes)
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
